← SynDRA
DAROVASERTIB
SynDRA canonical compound SYN0038679 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | GSK3B | PRKCA | PRKCQ |
| Mechanism of action | PKC inhibitor |
All known targets
Mechanisms of action (all sources)
- PRKCA INHIBITOR
- PRKCQ INHIBITOR
- PKC inhibitor
Cross-references
Synonyms
- IDE196
- LXS196
- IDE-196
- LXS-196
- NVP-LXS-196
- XXJXHXJWQSCNPX-UHFFFAOYSA-N
- LXS 196
- NVP-LXS196
- SCHEMBL17506262
- CHEMBL3982723
- BDBM251460
- EX-A2690
- BCP20781
- ZINC584641445
- CS-7529
- HY-101569
- US9452998, 9
- 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
- Darovasertib [USAN]
- E0YF0M8O09
- DAROVASERTIB [INN]
- UNII-E0YF0M8O09
- DAROVASERTIB [WHO-DD]
- Darovasertib (USAN)
- Example 9 [WO2016020864A1]
- Example 9 (WO2016020864A1)
- RefChem:130968
- PKC Inhibitor IDE196
- Protein Kinase C Inhibitor IDE196
- Protein Kinase C Inhibitor LXS196
- C22H23F3N8O
- MFCD31544328
- Darovasertib (LXS-196)
- orb1301656
- LXS196;IDE196
- SCHEMBL29392472
- SCHEMBL29913603
- GTPL11186
- CHEBI:233324
Look up DAROVASERTIB in the interactive SynDRA portal →